The Australian Competition and Consumer Commission has dropped a consumer case accusing NIB Health Funds of failing to alert customers to coverage changes in their policies, less than a month before trial was set to kick off in the long-running case.
Generic drug company Pharmacor has fired back in a patent lawsuit by Novartis, filing a cross-claim seeking to invalidate the Swiss drug giant’s patents for its blockbuster MS drug Gilenya.
Costly add-on therapies sold by Monash IVF to thousands of women undergoing IVF — including pre-implantation genetic testing — are the targets of a new class action investigation.
A judge weighing a $38.4 million settlement in a shareholder class action against aged care provider Estia Health has been told that two NSW Court of Appeal judgments barring class closure were āplainly wrongā, but in deciding whether to lock group members out of the settlement the judge says he wonāt need to grapple with the landmark rulings.
Staff members who worked for two Melbourne aged care providers will be removed as group members in class actions accusing the homes of negligently handling the coronavirus pandemic.
The companies behind the top selling Abilify medication have lost their latest bid for documents from the Commonwealth in a multimillion dollar dispute over the delayed listing of generic versions of their drug, with a judge saying the material could be only “of the most marginal relevance”.
Monash Health and LaTrobe Regional Health Service have been hit with a class action on behalf of junior doctors in Victoria who allege they were denied pay for overtime hours worked over the past six years, the second underpayments class action filed by junior doctors in the state.
NSW Health has hit back at a class action accusing it of failing to pay overtime hours to junior doctors, saying that because they did not submit an overtime claim they were taken to have worked the additional hours āof their own volitionā.
Hoping to avoid a lengthy trial like the 89-day hearing in the pelvic mesh class action against Johnson & Johnson’s Ethicon, a judge has suggested splitting up a class action hearing over TFS Manufacturing and IVS pelvic mesh products to focus on the question of the devices’ safety and efficacy first.
Australian regenerative medicine company Mesoblast faces a shareholder class action over disclosures related to its Remestemcel-L treatment for COVID-19 complications.